Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes

[1]  K. Sanderson,et al.  Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia , 2017, Applied Health Economics and Health Policy.

[2]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[3]  K. Sanderson,et al.  Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model , 2016, PharmacoEconomics - Open.

[4]  Sheri D Schully,et al.  A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.

[5]  J. Ioannidis,et al.  Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates. , 2016, JAMA.

[6]  G. Henderson,et al.  The Promise and Peril of Genomic Screening in the General Population , 2015, Genetics in Medicine.

[7]  E. Wood,et al.  Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron) , 2015, BMJ Open.

[8]  G. Palomaki,et al.  The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates , 2015, Genetics in Medicine.

[9]  V. Heinemann,et al.  Economic evaluation of genetic screening for Lynch syndrome in Germany , 2015, Genetics in Medicine.

[10]  D. English,et al.  Natural history of HFE simple heterozygosity for C282Y and H63D: A prospective 12‐year study , 2014, Journal of gastroenterology and hepatology.

[11]  D. Swinkels,et al.  Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis , 2014, BMC Health Services Research.

[12]  I. Frayling,et al.  A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. , 2014, Health technology assessment.

[13]  S. Leitman Hemochromatosis: the new blood donor. , 2013, Hematology. American Society of Hematology. Education Program.

[14]  Robert C. Green,et al.  Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium , 2013, Genetics in Medicine.

[15]  B. Knoppers,et al.  Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.

[16]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[17]  Elizabeth M Webber,et al.  Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies , 2013, Genetics in Medicine.

[18]  P. Romundstad,et al.  Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study , 2013, Scandinavian journal of gastroenterology.

[19]  Marylyn D. Ritchie,et al.  Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network , 2012, Genetics in Medicine.

[20]  M. Hulihan,et al.  Iron overload: what is the role of public health? , 2011, American journal of preventive medicine.

[21]  A. Morabia Re: "The emergence of translational epidemiology: from scientific discovery to population health impact". , 2011, American journal of epidemiology.

[22]  D. Gertig,et al.  HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 μg/L are at low risk of hemochromatosis , 2010, Hepatology.

[23]  J. Barton,et al.  How I treat hemochromatosis. , 2010, Blood.

[24]  E. Renard,et al.  The Southern French registry of genetic hemochromatosis: a tool for determining clinical prevalence of the disorder and genotype penetrance , 2010, Haematologica.

[25]  D. Petitti Hereditary hemochromatosis: population screening for gene mutations , 2009 .

[26]  John P. A. Ioannidis,et al.  Human Genome Epidemiology , 2009 .

[27]  P. Adams The Natural History of Untreated HFE-Related Hemochromatosis , 2009, Acta Haematologica.

[28]  M. Khoury,et al.  Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics , 2009, Public Health Genomics.

[29]  K. Kowdley,et al.  HFE-associated hereditary hemochromatosis , 2009, Genetics in Medicine.

[30]  W. Rogowski The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  J. Pankow,et al.  HFE C282Y Homozygosity Is Associated With Lower Total and Low-Density Lipoprotein Cholesterol: The Hemochromatosis and Iron Overload Screening Study , 2009, Circulation. Cardiovascular genetics.

[32]  J. Olynyk,et al.  Clinical penetrance of C282Y homozygous HFE hemochromatosis , 2008, Expert review of hematology.

[33]  H. Bonkovsky,et al.  Hereditary Hemochromatosis: Time for Targeted Screening , 2008, Annals of Internal Medicine.

[34]  J. Pankow,et al.  HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. , 2008, Translational research : the journal of laboratory and clinical medicine.

[35]  V. Felitti,et al.  Response: Screening for treatable disease is better than just screening for hemochromatosis , 2008 .

[36]  B. Nordestgaard,et al.  Hemochromatosis genotypes and risk of 31 disease endpoints: Meta‐analyses including 66,000 cases and 226,000 controls , 2007, Hepatology.

[37]  K. Hveem,et al.  Penetrance of the C28Y/C282Y genotype of the HFE gene , 2007, Scandinavian journal of gastroenterology.

[38]  B. Yawn,et al.  Screening for Hemochromatosis: Recommendation Statement , 2006, Annals of Internal Medicine.

[39]  E. Harris,et al.  Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force , 2006, Annals of Internal Medicine.

[40]  D. Reboussin,et al.  Liver diseases in the hemochromatosis and iron overload screening study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  M. Beaton,et al.  Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[42]  D. Hewett,et al.  Screening for hemochromatosis in asymptomatic subjects with or without a family history. , 2006, Archives of internal medicine.

[43]  R. Golub,et al.  Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians , 2005, Annals of Internal Medicine.

[44]  M. Aronson,et al.  Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians , 2005, Annals of Internal Medicine.

[45]  R. Williamson,et al.  Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis , 2005, The Lancet.

[46]  E. Thomson,et al.  Hemochromatosis and iron-overload screening in a racially diverse population. , 2005, The New England journal of medicine.

[47]  B. Nordestgaard,et al.  Hemochromatosis mutations in the general population: iron overload progression rate. , 2004, Blood.

[48]  J. Beilby,et al.  Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. , 2004, Mayo Clinic proceedings.

[49]  J. Koziol,et al.  Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA , 2002, The Lancet.

[50]  K. Hveem,et al.  Benefit of Population-based Screening for Phenotypic Hemochromatosis in Young Men , 2002, Scandinavian journal of gastroenterology.

[51]  B. Nordestgaard,et al.  Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study , 2001, The Lancet.

[52]  N. Milman,et al.  Clinically overt hereditary hemochromatosis in Denmark 1948–1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients , 2001, Annals of Hematology.

[53]  K. Hveem,et al.  Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons , 2001, Scandinavian journal of gastroenterology.

[54]  M. Khoury,et al.  Disease-related conditions in relatives of patients with hemochromatosis. , 2001, The New England journal of medicine.

[55]  L. Grummer-Strawn,et al.  Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.

[56]  R. Wolff,et al.  HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases , 2000, Annals of Internal Medicine.

[57]  J. Olynyk,et al.  A population-based study of the clinical expression of the hemochromatosis gene. , 1999, The New England journal of medicine.

[58]  I. Fellows,et al.  Haemochromatosis gene C282Y homozygotes in an elderly male population , 1999, The Lancet.

[59]  M. O'Leary,et al.  Prevalence of Hereditary Hemochromatosis in 16 031 Primary Care Patients , 1998, Annals of Internal Medicine.

[60]  C. Frampton,et al.  The significance of haemochromatosis gene mutations in the general population: implications for screening , 1998 .

[61]  D. Häussinger,et al.  Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.

[62]  S. Fargion,et al.  Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis , 1994, Hepatology.

[63]  B. Cesana,et al.  Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.

[64]  A. Bomford,et al.  Long term results of venesection therapy in idiopathic haemochromatosis. , 1976, The Quarterly journal of medicine.

[65]  J. Stockman Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .

[66]  Brian K. Crownover,et al.  Hereditary hemochromatosis. , 2013, American family physician.

[67]  M. Khoury,et al.  Evaluation of the validity and utility of genetic testing for rare diseases. , 2010, Advances in experimental medicine and biology.

[68]  J. Stockman Iron-Overload–Related Disease in HFE Hereditary Hemochromatosis , 2009 .

[69]  Zentrum München Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics , 2009 .

[70]  D. Reboussin,et al.  Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[71]  Jeffrey R. Botkin,et al.  Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .